PUBLICATIONS

• A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson’s Disease

  Mosley RL, Lu Y, Olson KE, Machhi J, Yan W, Namminga KL, Smith JR, Shandler SJ, Gendelman HE Front Cell Neurosci. 2019 Sep 18;13:421. doi: 10.3389/fncel.2019.00421. eCollection 2019.

• Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson’s Disease

  Olson KE, Bade AN, Schutt CR, Dong J, Shandler SJ, Boska MD, Mosley RL, Gendelman HE, Liu Y. Neurotherapeutics (2016). doi:10.1007/s13311-016-0449-z

• Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice

  Olson KE, Kosloski-Bilek KM, Anderson KM, Diggs BJ, Clark BE, Gledhill Jr JM, Shandler SJ, Mosley RL, and Gendelman HE. Journal of Neuroscience, 16 December 2015, 35(50): 16463-16478;